CPT1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL749997	1.00	20/20
SCHEMBL750850	1.00	20/20
SCHEMBL753364	1.00	20/20
SCHEMBL753204	0.83	20/20
SCHEMBL753382	0.83	20/20
SCHEMBL753532	0.74	20/20
SCHEMBL753641	0.60	20/20
SCHEMBL750018	1.00	19/20
SCHEMBL750776	1.00	19/20
SCHEMBL750901	1.00	19/20
SCHEMBL750959	1.00	19/20
SCHEMBL751311	1.00	19/20
SCHEMBL751629	1.00	19/20
SCHEMBL751759	1.00	19/20
SCHEMBL751912	1.00	19/20
SCHEMBL751957	1.00	19/20
SCHEMBL752083	1.00	19/20
SCHEMBL752206	1.00	19/20
SCHEMBL752219	1.00	19/20
SCHEMBL752295	1.00	19/20

Clinical trials — most relevant to CPT1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Identification of Carnitine-Responsive Cardiomyopathy	PHASE4	UNKNOWN
Omega 3 and Ischemic Stroke; Fish Oil as an Option	PHASE4	UNKNOWN
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Metabolic Manipulation in Chronic Heart Failure	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	PHASE2	RECRUITING
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia	nan	UNKNOWN
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
Lactate Profile and Fat Oxidation During Exercise	nan	COMPLETED
Effect of Carnitine on Uremic Cardiomyopathy	nan	COMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Effects of Carnitine Supplementation on Liver and Muscle	nan	COMPLETED
Physical Activity Following Surgery Induced Weight Loss	nan	COMPLETED
Metabolic and Mitochondrial Changes in Statin-Induced Myopathy	nan	COMPLETED
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
A Study to Improve Skeletal Muscle in Veterans With HIV	nan	RECRUITING
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome	nan	COMPLETED
Effects of Fish Oils on Inflammation and Insulin Resistance	nan	COMPLETED
The Effect of Lowered Physical Activity on Insulin Sensitivity and Lipid and Glucose Metabolism	nan	COMPLETED
PGC-1 and Mitochondrial Dysfunction in Diabetes	nan	COMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Epicardial Fat Tissue and Severity of Coronary Artery Disease in Diabetic vs Non Diabetic Patients	nan	UNKNOWN
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
Promotion of Weight Management	nan	ACTIVE_NOT_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CPT1B binder may also engage these)

Protein	Name	Similarity
Q63704	—	1.000	Q63704 →
Q924X2	—	1.000	Q924X2 →
P32198	—	1.000	P32198 →
Q8HY46	—	1.000	Q8HY46 →
Q58DK1	—	0.997	Q58DK1 →
CPT1A	Carnitine O-palmitoyltransferase 1, liver isoform	0.997	landscape →
Q68Y62	—	0.996	Q68Y62 →
Q8TCG5	—	0.995	Q8TCG5 →
Q90YJ9	—	0.994	Q90YJ9 →
P97742	—	0.993	P97742 →
Q03059	—	0.993	Q03059 →
F1LN46	—	0.991	F1LN46 →
Q8BGD5	—	0.991	Q8BGD5 →
CHAT	Choline O-acetyltransferase	0.988	landscape →
P11466	—	0.988	P11466 →
P32738	—	0.986	P32738 →
B2ZGJ1	—	0.986	B2ZGJ1 →
P07668	—	0.986	P07668 →
CRAT	Carnitine O-acetyltransferase	0.985	landscape →
P13222	—	0.984	P13222 →
Q704S8	—	0.984	Q704S8 →
O19094	—	0.983	O19094 →
P18886	—	0.981	P18886 →
Q9UKG9	—	0.981	Q9UKG9 →
Q9DC50	—	0.981	Q9DC50 →
Q2KJB7	—	0.980	Q2KJB7 →
Q7ZXE1	—	0.979	Q7ZXE1 →
P10759	—	0.979	P10759 →
KDM5D	Lysine-specific demethylase 5D	0.979	landscape →
Q922E4	—	0.979	Q922E4 →